鹭燕医药(002788) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥4,165,230,014.41, representing a 23.93% increase compared to the same period last year[8]. - Net profit attributable to shareholders was ¥64,700,746.54, reflecting a 26.32% year-over-year growth[8]. - The net profit after deducting non-recurring gains and losses was ¥64,624,978.47, which is a 31.46% increase from the previous year[8]. - The basic earnings per share (EPS) increased to ¥0.17, up 13.33% from ¥0.15 in the same quarter last year[8]. - The total profit for the quarter was CNY 83,805,463.91, an increase of 23.5% from CNY 67,836,575.86 year-on-year[46]. - Net profit for the quarter reached CNY 61,189,804.43, representing a 24.2% increase from CNY 49,260,498.13 in the previous year[46]. - The company reported a total comprehensive income of CNY 61,336,866.01, up from CNY 49,895,800.78 in the previous year[47]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,908,751,620.19, a 5.62% increase from the end of the previous year[8]. - The company's total liabilities amounted to CNY 6,434,966,283.73, up from CNY 6,028,634,871.80 year-over-year, indicating a growth of approximately 7%[39]. - The total owner's equity rose to CNY 2,473,785,336.46, up from CNY 2,406,248,470.45, which is an increase of approximately 2.8%[39]. - Total current liabilities were CNY 5,815,299,887.25, remaining unchanged from the previous period[60]. - Total non-current liabilities increased to CNY 213,334,984.55, with an adjustment of CNY 105,302,597.44[61]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥509,771,160.96, a decrease of 36.30% compared to the previous year[8]. - The total cash inflow from operating activities was CNY 4,540,455,694.72, an increase of 23.6% compared to CNY 3,671,739,573.99 in the previous period[53]. - The net cash outflow from operating activities was CNY -509,771,160.96, worsening from CNY -374,020,009.96 in the previous period[53]. - Cash inflow from financing activities totaled CNY 2,392,346,797.48, a slight decrease of 3.9% from CNY 2,490,391,985.12 in the previous period[54]. - The cash and cash equivalents at the end of the period were CNY 407,616,675.44, a decrease from CNY 413,284,226.01 in the previous period[54]. Investments and Projects - The construction in progress increased by 41.77% to ¥80,916,000, mainly due to investments in the logistics center project of Chengdu Hechuang Pharmaceutical Technology Co., Ltd.[16]. - The intangible assets rose by 42.63% to ¥161,504,900, attributed to the acquisition of land use rights for the Luyan Bozhou Modern Chinese Medicine Project[16]. - The company allocated RMB 12,633.36 million to the Fuzhou warehousing center project and RMB 11,008.86 million to the Putian logistics center project[26]. - The retail chain expansion project has completed construction with a total investment of CNY 8,000 million, achieving a progress rate of 71.89%[27]. - The company has made significant investments in expanding its warehousing and logistics capabilities, including projects in Xiamen and Fuzhou[26]. Legal and Compliance - The company signed a settlement agreement with multiple parties to prioritize project sales revenue for debt repayment[18]. - The company has initiated litigation against the equity transferor and guarantor of Chengdu Hechuang Pharmaceutical Group for breach of contract, claiming a total of RMB 43,623.1 million in damages[19]. - The company has received a court ruling requiring Guizhou Mingrun Construction Engineering Co., Ltd. to return a performance deposit of RMB 15 million[20]. - The company is currently in the process of appealing a court decision regarding a claim for remaining equity transfer payments of RMB 10 million[20]. Future Outlook - Future outlook includes potential market expansion and new product development, although specific figures or timelines were not provided in the report[44]. - The company has not reported any new product developments or market expansions in this quarter[68].